Centessa Pharmaceuticals plc discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor. SerpinPC, an activated protein C inhibitor, is in Phase IIa clinical development for the treatment of hemophilia A and B. The company also has emerging pipeline products under clinical proof of concept stage.
| Market Cap | 630.197 Million | Shares Outstanding | 97.403 Million | Avg 30-day Volume | 72.686 Thousand |
| P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -0.26 |
| Price to Revenue | 0.0 | Debt to Equity | 0.265 | EBITDA | -192.216 Million |
| Price to Book Value | 2.1296 | Operating Margin | 0.0 | Enterprise Value | 358.77 Million |
| Current Ratio | 10.347 | EPS Growth | 0 | Quick Ratio | 8.964 |
| 1 Yr BETA | 0.811 | 52-week High/Low | 8.65 / 3.0 | Profit Margin | 0.0 |
| Operating Cash Flow Growth | 0.0 | Free Cash Flow to Firm (FCFF) TTM | 0 | Free Cash Flow to Equity (FCFE) TTM | -131.335 Million |
| Altman Z-Score | -0.0262 |
Please sign in first
none
37.5 Thousand total shares from 1 transactions
37.5 Thousand total shares from 2 transactions
| Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
|---|---|---|---|---|
|
ROTMAN HARRIS SVP REGULATORY AFFAIRS |
|
33,500 | 2023-09-20 | 2 |
|
WEINHOFF GREGORY M CHIEF FINANCIAL OFFICER |
|
280,581 | 2023-06-30 | 4 |
|
CHAO DAVID M CHIEF ADMINISTRATIVE OFFICER |
|
276,212 | 2023-06-30 | 4 |
|
SAHA SAURABH CHIEF EXECUTIVE OFFICER |
|
897,099 | 2023-06-30 | 4 |
|
HUSSAIN IQBAL J GENERAL COUNSEL |
|
205,975 | 2023-06-30 | 4 |
|
BUSH TIA L CHIEF QUALITY OFFICER |
|
150,683 | 2023-06-30 | 5 |
|
GRAINGER DAVID J CHIEF INNOVATION OFFICER |
|
999,690 | 2023-06-30 | 4 |
|
0 | 2023-06-22 | 1 | |
|
0 | 2023-06-22 | 1 | |
|
GENERAL ATLANTIC GENPAR (BERMUDA), L.P. GENERAL ATLANTIC (LUX) S.A R.L. GENERAL ATLANTIC GENPAR (LUX) SCSP GENERAL ATLANTIC COOPERATIEF, L.P. GENERAL ATLANTIC PARTNERS (LUX), SCSP GENERAL ATLANTIC PARTNERS (BERMUDA) EU, L.P. GENERAL ATLANTIC PARTNERS (BERMUDA) IV, L.P. |
|
0 | 2023-06-22 | 1 |
|
0 | 2023-06-22 | 1 | |
|
0 | 2023-06-22 | 1 | |
|
0 | 2023-06-22 | 1 | |
|
0 | 2023-06-22 | 1 | |
|
YVER ANTOINE EVP & CHAIRMAN OF DEVELOPMENT |
|
783,066 | 2023-06-01 | 8 |
|
TEMPLEMAN THOMAS CHIEF TECHNOLOGY OFFICER |
|
188,244 | 2023-03-31 | 3 |
|
ANDERSON KAREN M. CHIEF PEOPLE OFFICER |
|
53,700 | 2023-02-01 | 3 |
|
SHAHIDI JAVAD CHIEF MEDICAL OFFICER |
|
165,000 | 2022-09-30 | 0 |
|
19,963,157 | 2022-03-21 | 0 | |
|
MEDICXI VENTURES MANAGEMENT (JERSEY) LTD |
|
19,963,157 | 2022-03-21 | 0 |
|
THORELL MARELLA CHIEF ACCOUNTING OFFICER |
|
53,101 | 2022-03-21 | 0 |
|
18,123,892 | 2021-12-02 | 0 | |
|
60,000 | 2021-11-18 | 0 | |
|
9,961,789 | 2021-05-27 | 0 | |
|
15,392,074 | 2021-05-27 | 0 | |
|
MEDICXI VENTURES MANAGEMENT (JERSEY) LTD |
|
15,392,074 | 2021-05-27 | 0 |
| Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-09-22 16:47:39 -0400 | 2023-09-20 | M | 6,234 | $3.85 | a | 70,984 | direct | yes | -1.3029 | 0.0 | 1 | -1.3029 | 2 | |||
| 2023-09-22 16:47:39 -0400 | 2023-09-20 | M | 6,234 | d | 43,666 | direct | yes | |||||||||
| 2023-09-22 16:47:39 -0400 | 2023-09-20 | M | 31,250 | $4.47 | a | 64,750 | direct | yes | -1.3029 | 0.0 | 1 | -1.3029 | 2 | |||
| 2023-09-22 16:47:39 -0400 | 2023-09-20 | M | 31,250 | d | 93,750 | direct | yes | |||||||||
| 2023-09-22 16:47:39 -0400 | 2023-09-20 | S | 37,484 | $6.29 | d | 33,500 | direct | yes | -1.3029 | 0.0 | 1 | -1.3029 | 2 |
* -
| Code | Definition |
|---|---|
| A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
| C | Conversion of derivative security |
| D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
| E | Expiration of short derivative position |
| F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
| G | Bona fide gift |
| H | Expiration (or cancellation) of long derivative position with value received |
| I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
| J | Other acquisition or disposition |
| L | Small acquisition under Rule 16a-6 |
| M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
| O | Exercise of out-of-the-money derivative security |
| P | Open market or private purchase of non-derivative or derivative security |
| S | Open market or private sale of non-derivative or derivative security |
| U | Disposition pursuant to a tender of shares in a change of control transaction |
| W | Acquisition or disposition by will or the laws of descent and distribution |
| X | Exercise of in-the-money or at-the-money derivative security |
| Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
| Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
|---|---|---|---|---|
| CENTESSA PHARMACEUTICALS-ADR CNTA | 2023-09-29 22:15:03 UTC | 4.2098 | 1.1102 | 55000 |
| CENTESSA PHARMACEUTICALS-ADR CNTA | 2023-09-29 21:45:04 UTC | 4.2098 | 1.1102 | 55000 |
| CENTESSA PHARMACEUTICALS-ADR CNTA | 2023-09-29 21:15:03 UTC | 4.2098 | 1.1102 | 55000 |
| CENTESSA PHARMACEUTICALS-ADR CNTA | 2023-09-29 20:45:05 UTC | 4.2098 | 1.1102 | 55000 |
| CENTESSA PHARMACEUTICALS-ADR CNTA | 2023-09-29 20:15:04 UTC | 4.2098 | 1.1102 | 55000 |
| CENTESSA PHARMACEUTICALS-ADR CNTA | 2023-09-29 19:45:04 UTC | 4.2098 | 1.1102 | 55000 |
| CENTESSA PHARMACEUTICALS-ADR CNTA | 2023-09-29 19:15:03 UTC | 0.0 | 0.0 | 55000 |
| CENTESSA PHARMACEUTICALS-ADR CNTA | 2023-09-29 18:45:03 UTC | 0.0 | 0.0 | 55000 |
| CENTESSA PHARMACEUTICALS-ADR CNTA | 2023-09-29 18:15:03 UTC | 0.0 | 0.0 | 55000 |
| CENTESSA PHARMACEUTICALS-ADR CNTA | 2023-09-29 17:45:03 UTC | 4.2098 | 1.1102 | 55000 |
| CENTESSA PHARMACEUTICALS-ADR CNTA | 2023-09-29 17:15:04 UTC | 4.2098 | 1.1102 | 55000 |
| CENTESSA PHARMACEUTICALS-ADR CNTA | 2023-09-29 16:45:04 UTC | 4.206 | 1.114 | 55000 |
| CENTESSA PHARMACEUTICALS-ADR CNTA | 2023-09-29 16:15:03 UTC | 4.206 | 1.114 | 55000 |
| CENTESSA PHARMACEUTICALS-ADR CNTA | 2023-09-29 15:45:04 UTC | 4.1206 | 1.1994 | 55000 |
| CENTESSA PHARMACEUTICALS-ADR CNTA | 2023-09-29 15:15:04 UTC | 4.1206 | 1.1994 | 60000 |
| CENTESSA PHARMACEUTICALS-ADR CNTA | 2023-09-29 14:45:04 UTC | 4.1206 | 1.1994 | 60000 |
| CENTESSA PHARMACEUTICALS-ADR CNTA | 2023-09-29 14:15:04 UTC | 4.1206 | 1.1994 | 60000 |
| CENTESSA PHARMACEUTICALS-ADR CNTA | 2023-09-29 13:45:03 UTC | 4.1047 | 1.2153 | 60000 |
| CENTESSA PHARMACEUTICALS-ADR CNTA | 2023-09-29 13:15:04 UTC | 4.1047 | 1.2153 | 60000 |
| CENTESSA PHARMACEUTICALS-ADR CNTA | 2023-09-29 12:45:05 UTC | 4.1047 | 1.2153 | 60000 |
| Holder | Issuer | Net Short Position | Position Date | Origin |
|---|---|---|---|---|
| Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund | CNTA | -2000.0 shares, $-12380.0 | 2023-06-30 | N-PORT |
